05322nam 2201393z- 450 991055754520332120220111(CKB)5400000000044155(oapen)https://directory.doabooks.org/handle/20.500.12854/76606(oapen)doab76606(EXLCZ)99540000000004415520202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierSphingolipidsFrom Pathology to Therapeutic Perspectives - A Themed Honorary Issue to Prof. Lina ObeidBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 online resource (292 p.)3-03943-957-X 3-03943-958-8 Although sphingolipids are ubiquitous components of cellular membranes, their abundance in cells is generally lower than glycerolipids or cholesterol, representing less than 20% of total lipid mass. Following their discovery in the brain-which contains the largest amounts of sphingolipids in the body-and first description in 1884 by J.L.W. Thudichum, sphingolipids have been overlooked for almost a century, perhaps due to their complexity and enigmatic nature. When sphingolipidoses were discovered, a series of inherited diseases caused by enzyme mutations involved in sphingolipid degradation returned to the limelight. The essential breakthrough came decades later, in the 1990s, with the discovery that sphingolipids were not just structural elements of cellular membranes but intra- and extracellular signaling molecules. It turned out that their lipid backbones, including ceramide and sphingosine-1-phosphate, had selective physiological functions. Thus, sphingolipids emerged as essential players in several pathologies including cancer, diabetes, neurodegenerative disorders, and autoimmune diseases. The present volume reflects upon the unexpectedly eclectic functions of sphingolipids in health, disease, and therapy. This fascinating lipid class will continue to be the subject of up-and-coming future discoveries, especially with regard to new therapeutic strategies.Sphingolipids Biology, life sciencesbicsscResearch & information: generalbicsscacid sphingomyelinasealbuminallyl carbamate derivativeanimal modelsanxietyanxiety-like behaviorapoptosisAspergillus fumigatusastrocytesautophagybarrier dysfunctionbeta-cellscalciumcancercardioprotectionceramidaseceramidasesceramideceramidesCLN3 diseaseCln3Δex7/8 micecoronary flowcortexcystic fibrosiscytokinesdepressiondepressive-like behaviorfingolimodflupirtineforebrainG-protein-coupled receptorsgangliosidesGαq/11hippocampushistone acetylationhypothalamushypoxiaimmunotherapyinfectious diseasesinflammationinsulininsulin resistanceischemia/reperfusionisletslong non-coding RNAmetastasismicroRNAmultiple sclerosismyocardial functionmyocardial infarctmyriocinn/aneurodegenerationneurodegenerative diseasesneuronsobesitypancreatic β cell fatephenotype switchingS1PS1P receptorS1P transporterS1P-lyase (SGPL1)S1P1-5SK1Smpd1sphingolipidssphingomyelinasesphingosine 1-phoshatesphingosine 1-phosphateSphingosine 1-phosphate (S1P)sphingosine 1-phosphate antagonistst/inhibitorssphingosine 1-phosphate metabolismsphingosine 1-phosphate receptorsphingosine 1-phosphate signalingsphingosine kinasesphingosine kinase 1sphingosine-1-phosphateSphingosine-1-phosphatespinster homolog 2stroketautranscription factortype 1 diabetestype 2 diabetesvasoconstrictionBiology, life sciencesResearch & information: generalvan Echten-Deckert Gerhildedt1307154van Echten-Deckert GerhildothBOOK9910557545203321Sphingolipids3028702UNINA01243nam0 2200349 i 450 VIA008052820251003044440.08877506091IT2000-8826 20130827d1999 ||||0itac50 baitaitz01i xxxe z01nMetabolismo e prodotti secondari delle pianteMassimo Maffeipresentazione di Carlo BicchiTorinoUTET università1999X, 350 p. :ill.24 cm.Biologia001CFI04840712001 BiologiaRicambio vegetaleApplicazioniFIRCFIC113723I572BIOCHIMICA14581.1912Maffei, Massimo <1957- >MILV16506407065396Bicchi, CarloCFIV023288ITIT-00000020130827IT-BN0095 NAP 01SALA $VIA0080528Biblioteca Centralizzata di Ateneo 01SALA 572 MAF me 0104 9000005575 VMA 1 v.A 2012092620120926 01Metabolismo e prodotti secondari delle piante1576426UNISANNIO